Lumos Diagnostics Completes A$10 Million Capital Raise

Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.

Lumos Diagnostics Holdings Ltd. has successfully completed a A$10.0 million capital raise, with the retail portion contributing A$6.9 million. This financial boost, strongly supported by investors including Tenmile and Ryder Capital, will propel the company’s growth and help expedite their U.S. objectives, including achieving CLIA waiver status for their FebriDx® point-of-care test in anticipation of the 2025 US flu season. Shares from the capital raise are expected to start trading on the ASX on 10 October 2024.

For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.